SCHEMBL6857576

SCHEMBL6857576

N[C@@H](CNc1cncc(-c2ccc3cnccc3n2)c1)Cc1c[nH]c2ccccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 19/20 0.64
PRKCG P05129 3/20 0.52
CDK1 P06493 3/20 0.52
PRKACA P17612 3/20 0.52
MAPK1 P28482 3/20 0.52
AKT2 P31751 3/20 0.52
AKT3 Q9Y243 3/20 0.52
DAPK3 O43293 2/20 0.52
PIM1 P11309 2/20 0.52
KDR P35968 2/20 0.52
GSK3A P49840 2/20 0.52
GSK3B P49841 2/20 0.52
RPS6KA3 P51812 2/20 0.52
CDK5 Q00535 2/20 0.52
PRKAA1 Q13131 2/20 0.52
DYRK1A Q13627 2/20 0.52
SRC P12931 2/20 0.52
CSNK2A2 P19784 2/20 0.52
PRKACG P22612 2/20 0.52
PRKACB P22694 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6857574 1.00 AKT1 (0.64) AKT1PRKCGCDK1PRKACAMAPK1
SCHEMBL6853421 0.84 AKT1 (0.63) AKT1PRKCGCDK1PRKACAMAPK1
SCHEMBL6849623 0.78 AKT1 (0.48) AKT1PRKCGPRKACAAKT2AKT3
SCHEMBL6857774 0.78 AKT1 (1.00) AKT1PRKCGCDK1PRKACAMAPK1
SCHEMBL6857776 0.78 AKT1 (1.00) AKT1PRKCGCDK1PRKACAMAPK1
SCHEMBL7201098 0.78 AKT1 (1.00) AKT1PRKCGCDK1PRKACAMAPK1
SCHEMBL6855184 0.77 AKT1 (1.00) AKT1PRKCGCDK1PRKACAMAPK1
SCHEMBL6855177 0.77 AKT1 (1.00) AKT1PRKCGCDK1PRKACAMAPK1
SCHEMBL6853486 0.77 AKT1 (1.00) AKT1PRKCGCDK1PRKACAMAPK1
SCHEMBL6853481 0.77 AKT1 (1.00) AKT1PRKCGCDK1PRKACAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831175-B2 Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine ABBOTT LABORATORIES 2004-12-14 US claimed
EP-1463505-A2 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER Abbott Laboratories (US) 2004-10-06 EP claimed
US-20030199511-A1 Kinase inhibitors ABBVIE INC. 2003-10-23 US claimed
US-20030187026-A1 Kinase inhibitors ABBOTT LABORATORIES 2003-10-02 US claimed
WO-2003051366-A2 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER ABBOTT LABORATORIES (US) 2003-06-26 WO claimed
US-6831175-B2 Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine ABBOTT LABORATORIES 2004-12-14 US disclosed
US-20030199511-A1 Kinase inhibitors ABBVIE INC. 2003-10-23 US disclosed
US-20030187026-A1 Kinase inhibitors ABBOTT LABORATORIES 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187026-A1 Kinase inhibitors MAP3K20, MAP3K19, MAP3K1 AKT1 119/4885PRKCG 152/4885CDK1 29/4885
US-20030199511-A1 Kinase inhibitors MAP3K20, MAP3K19, MAP3K1 AKT1 119/4885PRKCG 152/4885CDK1 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.